IPO News
Upcoming and recent IPOs, SPAC mergers, and direct listings. Track new stock market listings, IPO pricing, and first-day trading performance.
SK Hynix's $26.5B Nasdaq Debut Sparks Surge in Leveraged ETF Filings
SK Hynix's $26.5B Nasdaq debut at $149 per ADR triggers filings for leveraged single-stock ETFs. Analysis of premiums, Eos Energy rights, and Patriot SPAC reveals hidden costs of market access.
SK Hynix's $26.5B U.S. Debut Sparks Tech Rotation, Pressures Micron
Nasdaq futures dropped 0.35% as SK Hynix's $26.5B U.S. listing puts Micron's 21% premium in focus. Tech stocks face rotation amid rate hike bets and geopolitical risks.
SK hynix $26.5B Nasdaq Debut Tests AI Memory Demand
SK hynix's $26.5 billion Nasdaq listing draws strong demand, but U.S. memory stocks slip premarket, signaling potential rotation within the AI sector.
SpaceX Stock Struggles Near IPO Price Despite Bullish Analyst Targets
SpaceX stock remains near its Nasdaq opening price despite a flurry of bullish analyst reports. Shares trade at $148.89, with targets ranging from $200 to $900.
SK Hynix's Nasdaq Debut Raises $28 Billion Amid AI Chip Frenzy
SK Hynix's $28 billion Nasdaq ADR launch is oversubscribed 7x, driven by AI memory demand. The listing aims to narrow valuation gap with Micron.
SK Hynix's $28B US IPO Sees Massive Oversubscription, AI Demand Surges
SK Hynix's $28 billion US IPO saw over 7x demand, with the stock closely tied to AI supply chain. The ADRs begin trading on Nasdaq July 10.
SK Hynix launches $28B Nasdaq ADR to fuel AI memory expansion
SK Hynix (KRX:000660) kicked off a $28.1 billion Nasdaq ADR sale to fund 77% of its $55.9 trillion won AI memory capex, with shares starting Friday.
SpaceX Stock Wobbles Amid Index Rebalance and Wide Valuation Gap
SpaceX shares settle at $162, up from IPO but below peak, with analyst targets spanning $63 to $310 and index-tracking demand driving short-term volatility.
Apotex Health Shares Surge 4.75% on TSX, IPO Value Swells by C$620 Million
Apotex Health Corp. (TSX:APTX) rose 4.75% on Friday, lifting its IPO block value by C$620 million. The gains follow the close of its $100 million Cumberland Pharmaceuticals acquisition and a Health Canada nod for its generic semaglutide.